PRKCA and neoplasm: Inhibition of PDGFRβ-PKCα signaling specifically targets oncogene-transformed MECs that have undergone EMT and induces mesenchymal-to-epithelial transition (MET), suppressing tumor initiation and progression [40, 44, 45].